Akums Drugs & Pharmaceuticals Ltd

Akums Drugs Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Akums Drugs & Pharmaceuticals Ltd

₹ 521 -1.03%
15 May 2:51 p.m.
akums.in BSE: 544222 NSE: AKUMS
About

Established in 2004, Akums Drugs and Pharmaceuticals Limited is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services.[1]

Key Points

Business Profile[1] Akums Drugs is a Contract Development and Manufacturing Organization (CDMO) manufacturing tablets, capsules, liquid orals, vials, ampoules, blow-filled seals, topical preparations, eye drops, dry powder injections, and gummies.

Website BSE NSE
  • Market Cap ₹ 8,200 Cr.
  • Current Price ₹ 521
  • High / Low ₹ 623 / 409
  • Stock P/E 30.5
  • Book Value ₹ 211
  • Dividend Yield 0.00 %
  • ROCE 14.9 %
  • ROE 8.45 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company is almost debt free.

Cons

  • The company has delivered a poor sales growth of 9.87% over past five years.
  • Company has a low return on equity of 9.89% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare Nifty500 Shariah Nifty Microcap 250 Nifty Total Market Nifty500 Equal Weight

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
970 1,181 1,083 944 1,019 1,033 1,010 1,056 1,024 1,018 1,160 1,158
1,095 1,029 989 941 891 912 889 962 895 923 1,013 1,006
Operating Profit -125 152 93 3 128 121 121 94 129 94 147 152
OPM % -13% 13% 9% 0% 13% 12% 12% 9% 13% 9% 13% 13%
8 -21 10 10 7 17 19 26 27 32 16 34
Interest 12 14 12 12 13 12 5 5 23 23 24 24
Depreciation 30 30 32 34 34 35 45 40 37 38 40 40
Profit before tax -159 87 59 -33 87 92 91 75 96 66 100 121
Tax % 18% 62% -229% 20% 30% 27% 27% -99% 32% 35% 32% 33%
-187 33 195 -39 61 67 66 150 65 43 68 81
EPS in Rs -13.16 2.22 13.54 -2.89 4.08 4.14 4.14 9.38 4.03 2.59 4.21 5.38
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
1,464 1,651 2,414 2,723 3,672 3,655 4,178 4,118 4,359
1,340 1,507 2,240 2,485 3,761 3,361 4,055 3,654 3,837
Operating Profit 124 144 174 238 -89 294 123 465 522
OPM % 8% 9% 7% 9% -2% 8% 3% 11% 12%
6 6 26 11 7 15 8 69 109
Interest 23 22 20 7 17 46 51 35 94
Depreciation 31 38 67 70 95 113 126 153 155
Profit before tax 77 89 114 172 -193 150 -45 345 382
Tax % 51% 50% 62% 28% 30% 35% -102% 0% 33%
43 61 44 123 -251 98 1 344 256
EPS in Rs 366.55 523.23 335.61 943.49 -35.30 6.63 -0.28 21.49 16.21
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0% 18%
Compounded Sales Growth
10 Years: 10%
5 Years: 10%
3 Years: 6%
TTM: 6%
Compounded Profit Growth
10 Years: 16%
5 Years: 16%
3 Years: 29%
TTM: -17%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: -5%
Return on Equity
10 Years: %
5 Years: 6%
3 Years: 10%
Last Year: 8%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 1 1 1 1 14 29 29 31 31
Reserves 493 628 721 884 608 689 681 3,016 3,283
255 213 175 130 395 619 565 88 157
293 318 1,140 1,137 2,033 1,905 2,229 960 1,976
Total Liabilities 1,042 1,161 2,037 2,152 3,050 3,241 3,504 4,095 5,447
444 501 645 904 1,021 1,097 1,191 1,397 1,457
CWIP 0 11 57 17 31 103 195 163 177
Investments 0 18 6 20 0 0 0 0 0
598 632 1,329 1,212 1,998 2,041 2,118 2,535 3,814
Total Assets 1,042 1,161 2,037 2,152 3,050 3,241 3,504 4,095 5,447

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
72 89 28 131 32 177 498 465 1,181
-150 -123 -190 -109 -235 -305 -331 -548 -930
66 37 233 -91 236 125 -108 73 34
Net Cash Flow -11 4 71 -70 33 -4 59 -10 285
Free Cash Flow -78 -34 -34 49 -224 -110 212 201 958
CFO/OP 72% 98% 44% 74% -98% 93% 455% 118% 243%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 68 57 88 71 88 84 73 68 67
Inventory Days 114 115 99 93 112 117 90 102 110
Days Payable 67 60 105 74 92 91 76 96 87
Cash Conversion Cycle 115 112 82 90 109 111 87 74 89
Working Capital Days 78 73 55 66 49 46 40 71 66
ROCE % 14% 20% -16% 22% 2% 16% 15%

Insights

In beta
Mar 2016 Mar 2018 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Total Formulations Installed Production Capacity
Million Units

Log in to view insights

Please log in to see hidden values.

Login
Number of Manufacturing Facilities
Units
CDMO Customer Count
Units
Combined Capacity Utilization - Oral Solids
%
Combined Capacity Utilization - Sterile
%
Production Share of Total Drugs Consumed in India
%
R&D Spend as % of Adjusted Revenue
%
Number of SKUs
Units
DCGI Approvals
Units
Indian Domestic CDMO Market Share (by Value)
%
R&D Expenditure (Percentage of Turnover)
% ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
75.26% 75.26% 75.26% 75.26% 75.26% 75.26% 75.26%
7.34% 6.36% 5.77% 4.24% 2.27% 1.14% 1.38%
7.53% 6.99% 7.39% 8.85% 9.28% 14.41% 14.36%
7.14% 8.64% 8.84% 8.92% 10.46% 6.45% 6.29%
2.73% 2.73% 2.73% 2.73% 2.73% 2.73% 2.73%
No. of Shareholders 57,53168,41069,36669,42475,36576,86972,589

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls